Survey of actionable driver mutations KRAS and EGFR in non–small cell lung cancer

Molecularly targeted therapies have advanced treatment for certain cancers, such as lung cancer with specific EGFR or KRAS mutations. However, oftentimes the tumor becomes eventually treatment resistant. This may be partly because cancers driven by EGFR/KRAS mutations may also harbor additional co-occurring genetic alterations. In non-small cell lung cancer (NSCLC), aberrations in RNA splicing pathways have shown substantial implications for tumor behavior and therapeutic responsiveness. This study focuses on elucidating the interplay between RNA splicing defects and prominent NSCLC mutations. Learn more: https://meetings.asco.org/abstracts-presentations/232173